1.A clinical study of rituximab combined with autologous peripheral blood stem cell transplantation in treatment of B-cell non-Hodgkin′s lymphoma
Chongqing Medicine 2014;(28):3718-3721
Objective To evaluate the therapeutic effect of rituximab combined with autologous peripheral blood stem cell trans-plantation(APBSCT)in treatment of aggressive or refractory and recrrent B-cell non-Hodgkin′s lymphoma.Methods Forty-four patients with aggressive or refractory and recrrent B-cell non-Hodgkin′s lymphoma and treated with APBSCT in this department from Janauary 2007 to October 2013 were admitted.All the subjects were divided into 2 groups according to their own choice:22 pa-tients received rituximab treatment(treatment group)and 22 patients were treated without rituximab treatment(control group).For patients in treatment group,rituximab was used with chemotherapy or mobilization of stem cells before APBSCT for (2.9±1.1) times.After transplantation,IL-2 was used in both groups as maintenance treatment.And rituximab was used in the treatment group if the budget allows.Results The mononuclear cell count in treatment and control group was (13.01±4.22)×108/kg and (11.63±2.95)×108/kg(P=0.214).Hematopoietic reconstruction was successfully achieved in the both groups.No significant difference was found between 2 groups on the recovery time of neutrophilic granulocytes and platelets(P>0.05).All patients a-chieved complete remission(CR),at a median follow-up of 20 months(2-73 months),the disease relapsed in 2 patients in treatment group and 5 in control group.The 2-year overall survival rate in treatment group and control group were 95.0% and 75.1%,2-year progression-free survival rates were 82.4% and 74.5%,there were no significant difference between two groups(P=0.179, 0.393).Conclusion Rituximab combined with APBSCT in treatment of aggressive or refractory and recurrent B-cell lymphoma is feasible,however whether patients can benefit from long-term studies still need further research.Adding rituximab does not affect the hematopoietic stem cell collection and hematopoietic reconstitution.
3.Evaluation of tramadol for patient-controlled intravenious analgesia after abdominal total hysterectomy
Journal of Xi'an Jiaotong University(Medical Sciences) 1982;0(04):-
Objective To compare the effects and side effects of tramadol and morphine used for patient-controlled analgesia (PCA) delivery system after abdominal total hysterectomy Methods A single centre, randomized double-blind study of ASAⅠ~Ⅱ 80 patients undergoing elective abdominal total hysterectomy with inhalational anesthesia was performed. The patients were divided into four groups: tramadol group (group T, n=20), morphine+droperidol group (group M+D, n=20), morphine group (group M, n=20), and tramadol +droperidol group (group T+D, n=20). The study lasted for 24 h and the following data were collected: heart rate, blood pressure, respiration, VAS, sedation score (SS), Prince Henry score (PHS) as well as side effects. The consumption of analgesics within 24 hours were also recorded. Results VAS and PHS showed no differences between the four groups. M+D group was higher than the other groups in 4, 8, and 12 h of SS. The rates of postoperative nausea and vomiting (PONV) of group T and group M were higher than those of group M+D (P
4.Case of swelling in the lower extremities.
Chinese Acupuncture & Moxibustion 2016;36(4):448-448
Acupuncture Points
;
Acupuncture Therapy
;
Edema
;
pathology
;
therapy
;
Humans
;
Lower Extremity
;
pathology
;
Male
;
Middle Aged
5.The effect of mindfulness- based stress reduction on coping style and quality of life in liver cirrhosis ascites patients
Chinese Journal of Practical Nursing 2016;32(5):338-342
Objective To explore the effect of mindfulness- based stress reduction on coping style and quality of life in liver cirrhosis ascites patients. Methods Seventy- nine patients with liver cirrhosis ascites from March 2012 to May 2013 were selected as the control group with conventional treatment; 77 patients with liver cirrhosis ascites from October 2013 to December 2014 were selected as the observation group and were given mindfulness based stress reduction based on the control group. The coping style, the hope level and the quality of life between the two groups were compared by Simplified Coping Style Questionnaire, Herth Hope Scale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- c30). Results Before the treatment, two groups of positive and negative coping had no statistically significant difference (P>0.05). After the treatment of the observation group actively respond to score as follows: (25.44 ±2.61) points,significantly higher than the control group:(19.42±3.33) points, negative coping scores as follows: (9.76±1.89) points,significantly lower than the control group:(11.99±2.43) points, the differences between the two groups were significant (t=-10.468, 7.572, both P<0.01).Before the treatment, two groups of hope level had no statistically significant difference (P>0.05). The scores of the reality and the future of positive attitude, positive action, keep close relationship with others were (14.5±2.6), (15.1±2.4), (15.6±2.1) points after the treatment in the observation group, and (10.1±2.7), (10.5±2.3), (11.6±2.5) points in the control group, and there were significant differences (t=4.965, 5.569, 3.659, all P<0.01). After the treatment, observation group and control group patients in nausea and vomiting, constipation, diarrhea three dimension score difference had no statistical significance(P>0.05). The scores of physical function, role function, emotional function, cognitive function, social function, fatigue, pain, general health questionnaire, shortness of breath, insomnia, loss of appetite and the economic difficulties were (69.3±15.5), (74.1±22.6), (68.3±21.5), (79.7±23.4), (72.6±25.2), (42.1±26.1), (30.1±26.2), (55.6±15.6), (35.2±27.4), (36.2±28.7), (33.6±28.3), (25.6±24.3) points after the treatment in the observation group, and (58.6±21.2), (61.4±26.2), (75.6±20.4), (65.4±22.3), (55.4±28.7), (48.5±25.3), (37.6±29.2), (30.2±11.3), (41.6±28.7), (44.6±31.3), (40.2±30.4), (59.6±32.4) points in the control group, and there were significant differences (t=-39.369-15.621, P<0.01 or 0.05). Conclusions The mindfulness- based stress reduction can significantly improve the coping style in patients with liver cirrhosis and ascites, the level of hope and improve quality of life of patients, it is worth clinical promotion.
6.Expression of NANOG gene in cervical cancer and its significance
Wen WEN ; Jing JI ; Pengsheng ZHENG
Journal of Xi'an Jiaotong University(Medical Sciences) 2010;31(1):26-31
Objective To investigate the expression of NANOG gene in cervical cancer and its effect on the development of the cancer. Methods By using immunohistochemistry, NANOG expression levels were demonstrated in normal cervical tissues, cervical cancer in situ and cervical cancer tissues. Tumor sphere cells from cervical cancer tissue and their differentiated cells were injected into nude mice to observe the tumor growth. Results When compared with that of the normal cervical tissue, significantly higher NANOG protein expression level was found in cervical cancer and cervical cancer in situ (P<0.05). Tumor spheres were formed from the non-serum culture of cervical cancer tissue and the spheres could differentiate into epithelial-like cells. The sphere cells of cervical cancer caused tumor formation in nude mice. Conclusion The results suggest that cancer stem cells are present in cervical cancer and NANOG may play a crucial role in the development of cervical cancer.
7.Common clinical types and management of secondary glaucoma after ocular trauma
Jing, REN ; Jing-Wen, LIU ; Bo, QIN
International Eye Science 2016;16(6):1071-1075
?Ocular trauma related glaucoma is one of secondary glaucoma, which can lead to serious visual loss. According to the complex clinical findings and pathogenesis of ocular trauma related glaucoma, we divide traumatic secondary glaucoma into hyphema related glaucoma, angle recession related, lens injury related, adhesion and proliferation related. The treatment of secondary traumatic glaucoma with ocular trauma were different, specific treatment measures should be given according to the specific case to protect visual function.
8.Treatment for traumatic optic neuropathy with mouse nerve growth factor:a meta-analysis
International Eye Science 2015;(4):633-635
AIM:To evaluate the efficacy of treating traumatic optic neuropathy( TON) with mouse nerve growth factor.
METHODS: We searched the Cochrane Library, Pubmed, Medline, CNKI, Wanfang database and VIP to collect randomized controlled trials ( RCTs ) of using mouse nerve growth factor for TON. The quality of the included trials was assessed and poor-qualified trials were eliminated before the meta - analysis was conducted.
RESULTS:Seven RCTs with a total of 399 eyes included were retrieved, and OR=3. 78 with a 95%CI of [ 2. 35, 6.06], the difference was significant (P<0. 01).
CONCLUSION:The existing evidence supports that the prognosis of TON is better when mouse nerve growth factor are adopted in treatment, but there is still a need for well-planned, large-scale and multicenter RCTs to verify it.
9.Research progress of the association between PAX6 gene and retinal diseases
International Eye Science 2014;(9):1606-1607
PAX6 gene plays an important role in embryological development, and the mutation of this gene may result incongenital aniridia, retinoblastoma, macula hypoplasia, Peters' anomaly and so on. A brief introduction of the background PAX6 gene, and the association between PAX6 and retinal diseases were summarized in this review.
10. Folate receptor-mediated tumor-targeting nanoscale drug delivery system
Journal of International Pharmaceutical Research 2011;38(1):33-37
The folate receptor is highly selective tumor marker overexpressed in epithelioid cancer cells. As a targeting method ,folic acid mediated nanoscale drug delivery system has the advantages of folate-folate receptor's active targeting and nanoscale drug delivery's passive targeting. Active and passive targeting enable nanoscale drug delivery system release drugs in the location of tumor, which increases therapeutic index of drug and cuts down its side effect. In this article, we review folate-liposome , folate-dendrimer, folate-micelle, folate-nanophere and other folate receptor mediated tumor-targeting nanoscale drug delivery systems. Compared to traditional preparations, the novel nanoscale drug delivery system may offer a very promising approach for tumor-targeting therapy.